News & Publications

  • News

    December 23, 2020

    A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers
    Press release

  • Publication

    December 9, 2020

    HLA-A*02:01-directed chimeric antigen receptor/forkhead box P3-engineered CD4+ T cells adopt a regulatory phenotype and suppress established graft-versus-host disease


  • Publication

    December 4, 2020

    Re-examination of MAGE-A3 as a T-cell Therapeutic Target
    Journal of Immunotherapy

  • Publication

    November 9, 2020

    A Multivariate, Quantitative Assay that Disentangles Key Kinetic Parameters of Primary Human T Cell Function In Vitro


  • Perspective

    November 4, 2020

    Cancer T-cell Therapy: Building the Foundation for a Cure


  • News

    October 6, 2020

    A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics

    Press release

  • Publication

    October 2, 2020

    Engineered T Cells Directed at Tumors With Defined Allelic Loss

    Molecular Immunology

  • Presentation

    October 1, 2020

    Engineered T Cells Directed at Tumors With Defined Allelic Loss

    3rd Cell Therapies and Immunotherapy Conference

  • Poster

    August 31,  2020

    A Computational Approach to Predict Off-target Peptide Selectivity of pMHC Targeting Therapeutics

    The Essential Protein Engineering & Cell Therapy Summit Virtual

  • Publication

    August 5, 2020

    Structure-function Relationships of Chimeric Antigen Receptors in Acute T Cell Responses to Antigen

    Molecular Immunology

  • Publication

    November 21, 2019

    Single Variable Domains from the T Cell Receptor β Chain Function as Mono-and Bifunctional CARs and TCRs

    Scientific Reports

  • News

    November 5, 2019


30301 Agoura Road #210, Agoura Hills, CA, 91301

© 2019 A2 Biotherapeutics, Inc.